Radiotherapy and Oncology最新文献

英文中文

3550: What does quality in education practice and research look like? 3550:教育实践和研究的质量是什么样子的？

IF 5.7 1区医学 Q1 ONCOLOGY

Radiotherapy and Oncology

Pub Date : 2024-08-30 DOI: 10.1016/s0167-8140(24)03454-6

Daniel W. Golden

引用次数: 0

Single preoperative radiation therapy with delayed surgery for low-risk breast cancer: Oncologic outcome, toxicity and cosmesis of the SPORT-DS phase I trial 低风险乳腺癌术前单次放射治疗与延迟手术：SPORT-DS I 期试验的肿瘤学结果、毒性和外观。

IF 4.9 1区医学 Q1 ONCOLOGY

Radiotherapy and Oncology

Pub Date : 2024-08-30 DOI: 10.1016/j.radonc.2024.110515

Background

A novel approach using single-fraction preoperative partial breast irradiation (PBI) for low-risk breast cancer is under study. We sought to investigate the rate of pathologic response (pR), toxicities and cosmetic results related to this new treatment strategy.

Methods

Women of 65 years or older with stage I unifocal luminal A breast cancer were eligible for inclusion in this phase I prospective trial. Patients received a single 20 Gy dose of PBI followed by breast-conserving surgery (BCS) 3 months later. The primary endpoint was the pR rate, and the secondary endpoints were radiation therapy-related toxicity and cosmetic results.

Results

Thirteen patients were treated, with a median age of 71. Eleven patients (84.6 %) had pR with a median residual cellularity of 1 % (range: 0–10 %). At median follow-up of 48.5 months, no recurrences or cancer-related deaths were recorded. Acute radiation therapy-related toxicity were limited to grade 1 dermatitis and breast pain. At the 1-year follow-up, there were one grade 2 fat necrosis and two grade 3 toxicities (wound infection and hematoma). Only grade 1 toxicities remained at 2 years, but one grade 2 toxicity (fibrosis/induration) developed by the 3-year follow-up. Three-year patient-reported cosmetic outcomes were good or excellent in 60 % of patients.

Conclusions

Single-fraction preoperative PBI preceding BCS for low-risk breast cancer is feasible, relatively well tolerated and leads to a high level of pR. The 3-month interval after PBI seems to place surgery in a post-radiation inflammatory phase. Further delay between PBI and surgery could improve pR and cosmetic outcome. NCT03917498.

背景：目前正在研究一种针对低风险乳腺癌的新方法，即术前单次乳腺部分照射（PBI）。我们试图研究与这种新治疗策略相关的病理反应率（pR）、毒性和美容效果：方法：65 岁或 65 岁以上患有 I 期单发管腔 A 型乳腺癌的妇女均有资格参加这项 I 期前瞻性试验。患者接受单次20 Gy剂量的PBI治疗，3个月后进行保乳手术（BCS）。主要终点是pR率，次要终点是放疗相关毒性和美容效果：13名患者接受了治疗，中位年龄为71岁。11名患者（84.6%）获得了pR，中位残留细胞率为1%（范围：0-10%）。中位随访时间为 48.5 个月，无复发或癌症相关死亡记录。急性放疗相关毒性仅限于一级皮炎和乳房疼痛。在 1 年的随访中，有 1 例 2 级脂肪坏死和 2 例 3 级毒性反应（伤口感染和血肿）。2 年随访时只有 1 级毒性反应，但 3 年随访时出现了 1 例 2 级毒性反应（纤维化/硬化）。60%的患者三年后的美容效果良好或极佳：结论：低风险乳腺癌患者在 BCS 之前进行单次术前 PBI 是可行的，耐受性相对较好，并能获得较高的 pR。PBI 后的 3 个月间隔期似乎使手术处于放疗后炎症期。进一步推迟 PBI 和手术之间的时间可提高 pR 和美容效果。NCT03917498。

{"title":"Single preoperative radiation therapy with delayed surgery for low-risk breast cancer: Oncologic outcome, toxicity and cosmesis of the SPORT-DS phase I trial","authors":"","doi":"10.1016/j.radonc.2024.110515","DOIUrl":"10.1016/j.radonc.2024.110515","url":null,"abstract":"<div><h3>Background</h3><p>A novel approach using single-fraction preoperative partial breast irradiation (PBI) for low-risk breast cancer is under study. We sought to investigate the rate of pathologic response (pR), toxicities and cosmetic results related to this new treatment strategy.</p></div><div><h3>Methods</h3><p>Women of 65 years or older with stage I unifocal luminal A breast cancer were eligible for inclusion in this phase I prospective trial. Patients received a single 20 Gy dose of PBI followed by breast-conserving surgery (BCS) 3 months later. The primary endpoint was the pR rate, and the secondary endpoints were radiation therapy-related toxicity and cosmetic results.</p></div><div><h3>Results</h3><p>Thirteen patients were treated, with a median age of 71. Eleven patients (84.6 %) had pR with a median residual cellularity of 1 % (range: 0–10 %). At median follow-up of 48.5 months, no recurrences or cancer-related deaths were recorded. Acute radiation therapy-related toxicity were limited to grade 1 dermatitis and breast pain. At the 1-year follow-up, there were one grade 2 fat necrosis and two grade 3 toxicities (wound infection and hematoma). Only grade 1 toxicities remained at 2 years, but one grade 2 toxicity (fibrosis/induration) developed by the 3-year follow-up. Three-year patient-reported cosmetic outcomes were good or excellent in 60 % of patients.</p></div><div><h3>Conclusions</h3><p>Single-fraction preoperative PBI preceding BCS for low-risk breast cancer is feasible, relatively well tolerated and leads to a high level of pR. The 3-month interval after PBI seems to place surgery in a post-radiation inflammatory phase. Further delay between PBI and surgery could improve pR and cosmetic outcome. NCT03917498.</p></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0167814024034935/pdfft?md5=879f2ec17f9df16065810dcc6e0ee43e&pid=1-s2.0-S0167814024034935-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142111432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

3622: Single-cell analysis of lung responses to radiation injury 3622：辐射损伤肺部反应的单细胞分析

IF 5.7 1区医学 Q1 ONCOLOGY

Radiotherapy and Oncology

Pub Date : 2024-08-30 DOI: 10.1016/s0167-8140(24)03475-3

Charles Fouillade

引用次数: 0

10: Preservation of vision with fully fractionated stereotactic RT for posterior choroidal melanoma. 10：用全分层立体定向 RT 治疗后脉络膜黑色素瘤，保留视力。

IF 5.7 1区医学 Q1 ONCOLOGY

Radiotherapy and Oncology

Pub Date : 2024-08-30 DOI: 10.1016/s0167-8140(24)03482-0

Claire Phillips, Elena Ungureanu, Mathias Bressel, Roderick O'Day, John McKenzie, Daniel McKay, Haris Ahmad, Lotte Fog, Joseph Sia, Fred Chen, William Campbell

引用次数: 0

3473: Radiation-related toxicity: Where do we stand and where do we go from here? 3473:辐射相关毒性：何去何从？

IF 5.7 1区医学 Q1 ONCOLOGY

Radiotherapy and Oncology

Pub Date : 2024-08-30 DOI: 10.1016/s0167-8140(24)03404-2

Dirk De Ruysscher

引用次数: 0

3552: Working within the framework of MDR in clinical radiotherapy 3552: 在临床放射治疗的 MDR 框架内开展工作

IF 5.7 1区医学 Q1 ONCOLOGY

Radiotherapy and Oncology

Pub Date : 2024-08-30 DOI: 10.1016/s0167-8140(24)03456-x

Eva Onjukka

引用次数: 0

3514: The elderly patient unfit for cisplatin: Then what? 3514:不适合使用顺铂的老年患者：然后呢？

IF 5.7 1区医学 Q1 ONCOLOGY

Radiotherapy and Oncology

Pub Date : 2024-08-30 DOI: 10.1016/s0167-8140(24)03436-4

Alexander Rühle

引用次数: 0

Post-hoc analysis of clinicopathological factors affecting lateral lymph node metastasis based on STELLAR study for rectal cancer 根据直肠癌 STELLAR 研究对影响侧淋巴结转移的临床病理因素进行事后分析。

IF 4.9 1区医学 Q1 ONCOLOGY

Radiotherapy and Oncology

Pub Date : 2024-08-30 DOI: 10.1016/j.radonc.2024.110512

Purpose

In post-hoc analyses of phase III randomized controlled study (STELLAR), to analyze the prognostic impact of lateral pelvic lymph node (LPLN) metastasis in locally advanced rectal cancer (LARC).

Methods

LPLN metastasis was defined as a short diameter > 7 mm on magnetic resonance imaging (MRI). The study included 591 patients with LARC. All patients received neoadjuvant (chemo)radiotherapy combined with radical resection.

Results

Among 591 patients, 99 (16.8 %) were diagnosed with LPLN metastasis, mostly with unilateral metastasis (79.8 %), with internal iliac lymph node metastasis being more common (81.8 %). Significant differences were found among with and without LPLN metastasis in rectal segmentation (P=0.001), N disease (P<0.001), mesenteric LN metastasis or not (P=0.030). The median follow-up time was 34.0 months, three-year disease-free survival (DFS), overall survival (OS), and metastasis-free survival (MFS) were significantly lower in LPLN metastatic group than those in LPLN non-metastatic group (51.4 % vs. 68.2 %, P<0.001; 71.8 % vs. 84.2 %, P=0.006; 60.8 % vs. 80.1 %, P<0.001), respectively; while there were no significant differences in locoregional recurrence (11.4 % vs. 8.5 %, P=0.564). Multivariate analysis found that LPLN metastasis was an independent prognostic factor affecting DFS (P=0.005), OS (P=0.036), MFS (P=0.001). No significantly survival benefit was observed for the short-term radiotherapy based total neoadjuvant therapy compared to long-term concurrent chemoradiotherapy.

Conclusions

LPLN metastasis observed by MRI should be considered in LARC patients, especially in populations with low rectal cancer, N2 disease, and mesenteric LN metastasis. LPLN metastasis diagnosed by MRI is a significant and independent risk factor and is associated with worse DFS, OS, MFS.

目的：在第三期随机对照研究（STELLAR）的事后分析中，分析局部晚期直肠癌（LARC）盆腔侧淋巴结（LPLN）转移对预后的影响：所有患者均接受了新辅助（化疗）放疗和根治性切除术：591例患者中，99例（16.8%）确诊为LPLN转移，大部分为单侧转移（79.8%），其中髂内淋巴结转移更为常见（81.8%）：LARC患者，尤其是低位直肠癌、N2病变和肠系膜LN转移的患者，应考虑MRI观察到的LPLN转移。MRI 诊断出的 LPLN 转移是一个重要的独立危险因素，与较差的 DFS、OS 和 MFS 相关。

{"title":"Post-hoc analysis of clinicopathological factors affecting lateral lymph node metastasis based on STELLAR study for rectal cancer","authors":"","doi":"10.1016/j.radonc.2024.110512","DOIUrl":"10.1016/j.radonc.2024.110512","url":null,"abstract":"<div><h3>Purpose</h3><p>In post-hoc analyses of phaseIII randomized controlled study(STELLAR), to analyzethe prognostic impact oflateral pelvic lymph node (LPLN)metastasis in locally advanced rectal cancer (LARC).</p></div><div><h3>Methods</h3><p>LPLN metastasis was defined as a short diameter > 7 mm on magnetic resonance imaging (MRI).The studyincluded 591 patients with LARC.All patients received neoadjuvant (chemo)radiotherapy combined withradical resection.</p></div><div><h3>Results</h3><p>Among 591 patients, 99 (16.8 %) were diagnosed with LPLN metastasis, mostly with unilateral metastasis (79.8 %), with internal iliac lymph node metastasis being more common (81.8 %).Significant differences were found among with and without LPLN metastasis in rectal segmentation (P=0.001),N disease (P<0.001), mesenteric LN metastasis or not (P=0.030). The median follow-up timewas 34.0 months, three-year disease-free survival (DFS),overall survival (OS), andmetastasis-free survival (MFS)were significantly lower in LPLN metastaticgroup than those in LPLN non-metastaticgroup (51.4 % vs. 68.2 %, P<0.001; 71.8 % vs. 84.2 %, P=0.006; 60.8 % vs. 80.1 %,P<0.001), respectively; while there were no significant differences in locoregional recurrence(11.4 % vs. 8.5 %, P=0.564). Multivariate analysis found that LPLN metastasis was an independent prognostic factor affecting DFS (P=0.005), OS (P=0.036),MFS (P=0.001).No significantly survival benefit was observed for the short-term radiotherapy based total neoadjuvant therapy compared to long-term concurrent chemoradiotherapy.</p></div><div><h3>Conclusions</h3><p>LPLN metastasis observed byMRI should be considered in LARC patients, especially in populations with lowrectal cancer, N2 disease, and mesenteric LN metastasis. LPLN metastasis diagnosed by MRI is a significant and independent risk factor and is associated with worse DFS, OS, MFS.</p></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S016781402403490X/pdfft?md5=eb2b10c6528aa4b78827cd9a7e71de50&pid=1-s2.0-S016781402403490X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142111428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

3505: Surgery: When and how? 3505: 外科手术：何时、如何？

IF 5.7 1区医学 Q1 ONCOLOGY

Radiotherapy and Oncology

Pub Date : 2024-08-30 DOI: 10.1016/s0167-8140(24)03428-5

Magnus Nilsson

引用次数: 0

3488: Recent advances in dermatooncology – ESTRO view 3488:皮肤肿瘤学的最新进展 - ESTRO观点

IF 5.7 1区医学 Q1 ONCOLOGY

Radiotherapy and Oncology

Pub Date : 2024-08-30 DOI: 10.1016/s0167-8140(24)03414-5

Agata Rembielak

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Radiotherapy and Oncology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀